Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087056 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
A Phase 2 study of Meningitis, Meningococcal, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT05087056: Active Phase 2 study of Meningitis, Meningococcal, sponsored by GlaxoSmithKline.
NCT05087056 is a Phase 2 study of Meningitis, Meningococcal that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 302 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (127% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05087056, a Phase 2 study of Meningitis, Meningococcal, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
Primary Outcome
The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT MenABCWY vaccine
Study Locations (20)
Nebraska
- GSK Investigational Site - Grand Island
- GSK Investigational Site - Lincoln
- GSK Investigational Site - Omaha
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
Montana
- GSK Investigational Site - Missoula
- GSK Investigational Site - Missoula
New York
- GSK Investigational Site - Binghamton
- GSK Investigational Site - Endwell
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Tucson
California
- GSK Investigational Site - Ventura
District of Columbia
- GSK Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2027-02-05 |
| Phase | Phase 2 |
What the registry record for NCT05087056 still lists
NCT05087056 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (127% higher).
The record links to 1 condition, with Meningitis, Meningococcal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05087056 names 20 study sites across 15 states, led by Nebraska, Florida, Montana.
Frequently Asked Questions
What is clinical trial NCT05087056 about?
NCT05087056 is a clinical study titled "Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents". The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
What is the current status of trial NCT05087056?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2021-11-18. Estimated completion is 2027-02-05.
What conditions does trial NCT05087056 study?
This clinical trial studies the following conditions: Meningitis, Meningococcal.
What interventions are being tested in trial NCT05087056?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), MenABCWY vaccine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05087056?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05087056 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningitis, Meningococcal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05087056's enrollment target sits among peer trials
302 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI